Cargando…
Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells
BACKGROUND: The bone-targeting agent zoledronic acid (ZOL) increases breast cancer survival in subsets of patients, but the underlying reasons for this protective effect are unknown. ZOL modulates the activity of osteoclasts and osteoblasts, which form hematopoietic stem cell niches, and therefore m...
Autores principales: | Ubellacker, Jessalyn M., Haider, Marie-Therese, DeCristo, Molly J., Allocca, Gloria, Brown, Nicola J., Silver, Daniel P., Holen, Ingunn, McAllister, Sandra S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339994/ https://www.ncbi.nlm.nih.gov/pubmed/28264701 http://dx.doi.org/10.1186/s13058-017-0815-8 |
Ejemplares similares
-
The unresolved role of systemic factors in bone metastasis
por: Ubellacker, Jessalyn M., et al.
Publicado: (2016) -
Modifying the osteoblastic niche with zoledronic acid in vivo—Potential implications for breast cancer bone metastasis
por: Haider, Marie-Therese, et al.
Publicado: (2014) -
Accounting for tumor heterogeneity when using CRISPR-Cas9 for cancer progression and drug sensitivity studies
por: Olive, Jessica F., et al.
Publicado: (2018) -
The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells
por: Brown, Hannah K, et al.
Publicado: (2011) -
The bone metastasis niche in breast cancer-potential overlap with the haematopoietic stem cell niche in vivo
por: Allocca, Gloria, et al.
Publicado: (2019)